(NASDAQ: VIR) Vir Biotechnology's forecast annual revenue growth rate of -5.22% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Vir Biotechnology's revenue in 2024 is $79,599,000.On average, 4 Wall Street analysts forecast VIR's revenue for 2024 to be $11,601,451,526, with the lowest VIR revenue forecast at $7,673,709,552, and the highest VIR revenue forecast at $18,884,944,784. On average, 3 Wall Street analysts forecast VIR's revenue for 2025 to be $8,852,385,897, with the lowest VIR revenue forecast at $2,874,919,908, and the highest VIR revenue forecast at $14,449,431,816.
In 2026, VIR is forecast to generate $9,712,412,813 in revenue, with the lowest revenue forecast at $3,062,680,887 and the highest revenue forecast at $15,020,878,272.